ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1972

Quantifying Sjogren’s Disease Burden: UHFUS Evaluation of the Number and Severity of Involved Exocrine Gland

Giovanni Fulvio1, Rossana Izzetti2, Valentina Donati3, Caterina Porciani4, Silvia Fonzetti1, Gaetano La Rocca1, Inmaculada Conception Navarro García1, Francesco Ferro5, Chiara Baldini1 and Marta Mosca1, 1University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, 2University of Pisa, Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine - Unit of Dentistry and Oral Surgery, Pisa, 3Azienda Ospedaliero-Universitaria Pisana, Unit of Pathological Anatomy 2, Pisa, Italy, 4University of Pisa, Department of Clinical and Experimental Medicine - Immmunology and Allergology Unit, Pisa, Italy, 5Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy

Meeting: ACR Convergence 2024

Keywords: Disease Activity, OMERACT, Sjögren's syndrome, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Imaging of Rheumatic Diseases Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Ultra-high frequency ultrasound (UHFUS) has emerged as a promising tool for evaluating small superficial exocrine glands including lachrymal (LGs) and labial salivary glands (LSGs) in Sjogren’s disease (SD). The combined use of UHFUS and conventional US of major salivary glands may therefore allow to simultaneously visualize all the exocrine glands. A limited number of studies have explored the diagnostic potential of assessing multiple exocrine glands in patients with suspected SD. The aim of the study was to explore whether the assessment of  the number of glands involved and  of the severity of glandular involvement, as assessed by the presence of very hypoechoic areas (VHA), may improve patients’ diagnosis and phenotypic stratification.

Methods: Consecutive patients with suspected SD, undergoing LSG biopsy, were included. LSGs, LGs and MSGs were examined using 70 MHz, 48 MHz and 18 MHz probes, respectively. Patients were positioned supine with closed eyelids. Glandular inhomogeneity was evaluated with a semiquantitative score (OMERACT Score, 0-3). We specifically investigated the presence of VHA such as the typical findings of lymphoma described in literature and/or the new pattern characterized by the presence of multiple very hypoechoic areas grouping patients as follows:  VHA absent in all the glands, VHA in either LSGs or LGs gland (single positive VHA) and VHA in both the glands (double positive VHA). Serum from each patient was tested for anti-Ro52, anti-Ro60, and anti-SSB/La abs, evaluating the quantitative titer of the autoantibodies with band densitometry. Descriptive statistics were performed using SPSS.

Results: A total of 71 subjects (10 males and 61 females) were evaluated. Out of them, 28 met the ACR2016 criteria for SD. The k-Cohen concordance between LGs and LSGs in gray scale was 0.600 (p< 0.001), between MSGs and LSGs was 0.553 (p=0.001) and between MSGs and LGs was 0.425 (p=0.013). ROC curve analysis indicated that LGUHFUS and LSGUHFUS, at the optimal cut-off value of 2, identified SD and sicca controls with good diagnostic accuracy (AUC=0.836, 95%CI: 0.702-0.970 and AUC=0.899, 95%CI: 0.807-0.991). The sum of the score showed an excellent accuracy (AUC=0.909, 95%CI: 0.820-0.997, Fig. 1) with all the subjects presenting a UHFUS score >2 in both LSGs and LGs receiving the diagnosis of SD. Subjects with a positive UHFUS score in all the salivary and lachrymal glands (double positive) showed higher inflammation at the tissue level, autoantibody titers, and ESSDAI activity compared to subjects with UHFUS abnormalities only in the lachrymal or salivary glands. Patients with a UHFUS < 2 in all the glands had the lowest values of tissue inflammatory biomarkers and autoantibody titers (Fig. 2). As the presence of VHA in the glands increases, histological inflammatory biomarkers, autoantibody titers, immunoglobulin levels and ESSDAI increase, whereas C4 and lymphocyte levels decrease (Fig. 3).

Conclusion: Evaluating multiple exocrine glands with UHFUS increases the diagnostic power of  traditional ultrasound. Furthermore, as in joint ultrasound, an increase in the number and severity of exocrine glands is associated with higher patient activity, as measured by ESSDAI, and biohumoral activity.

Supporting image 1

Figure 1 – ROC curve, LG Lachrymal Glands, LSG Labial Salivary Glands

Supporting image 2

Figure 2 – UHFUS positivity in Lachrymal and Labial Glands (Double Positive), only in one gland (Single positive) and in none of the glands (negative). Nfoci Number of foci, ELS Ectopic Lymphoid Structures, ESSDAI EULAR Sjögren’s syndrome disease acivity

Supporting image 3

Figure 3 – VHA in Lachrymal and Labial Glands (Double Positive VHA), only in one gland (Single positive VHA) and in none of the glands (negative). Nfoci Number of foci, ELS Ectopic Lymphoid Structures, ESSDAI EULAR Sjögren’s syndrome disease acivity


Disclosures: G. Fulvio: None; R. Izzetti: None; V. Donati: None; C. Porciani: None; S. Fonzetti: None; G. La Rocca: None; I. Navarro García: None; F. Ferro: None; C. Baldini: Amgen, 1, 2, Aurinia, 1, GlaxoSmithKlein(GSK), 2, 5, 6, 12, Paid Instructor, johnson & johnson, 1, Novartis, 5, Sanofi, 2, 6, 12, Paid Instructor, Viela, 5; M. Mosca: AbbVie, 2, 6, AstraZeneca, 2, 6, GSK, 2, 5, 6, Idorsia, 2, Janssen, 6, Lilly, 6, Otsuka, 2, 6, UCB, 2.

To cite this abstract in AMA style:

Fulvio G, Izzetti R, Donati V, Porciani C, Fonzetti S, La Rocca G, Navarro García I, Ferro F, Baldini C, Mosca M. Quantifying Sjogren’s Disease Burden: UHFUS Evaluation of the Number and Severity of Involved Exocrine Gland [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/quantifying-sjogrens-disease-burden-uhfus-evaluation-of-the-number-and-severity-of-involved-exocrine-gland/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/quantifying-sjogrens-disease-burden-uhfus-evaluation-of-the-number-and-severity-of-involved-exocrine-gland/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology